Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Inversagen AI
San Diego, California, United Statesgatchealth.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Inversagen AI is a biotechnology company and joint venture formed to advance age-related disease treatments and oncology therapeutics. The company is currently funding and co-developing ozuriftamab vedotin (Oz-V), a conditionally active biologic antibody-drug conjugate targeting ROR2, for a Phase 3 registrational trial in oropharyngeal squamous cell carcinoma (OPSCC).
- Therapeutic areas
- OncologyImmunologyOther
- Modalities
- Antibody-drug conjugateMonoclonal antibodyConditionally Active Biologic
- Industry
- Biotech
02
Partnerships
BioAtlaGATC Health
Beyond the preview
Go deeper on Inversagen AI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inversagen AI.